Background: The Luminal A molecular subtype of clinical breast cancer expresses estrogen receptor (ER) and progesterone receptor (PR), but lacks the expression of HER-2 oncogene. This cancer subtype responds to endocrine therapy involving the use of selective estrogen receptor modulators or inhibitors of estrogen biosynthesis. Conventional therapeutic options are frequently associated with acquired tumor resistance and systemic toxicity, and therefore, emphasize a need for identification of promising new non-toxic agents for secondary prevention. Nutritional substances that do not incur long-term toxicity represent ideal candidates. Nutritional herbs have been used in traditional Chinese medicine for a variety of health related issues, including prevention of breast cancer.
Study Rationale I
• Global gene profiling of differentially expressed genes in clinical breast cancer provides a refined molecular classification of cancer subtypes (1).
• Tumors expressing estrogen receptor (ER) and progesterone receptor (PR) but lacking the expression of human epidermal growth factor receptor-2 (HER-2) are classified as the Luminal A subtype (2).
• The human carcinoma derived MCF-7 cells are ER+, PR+ and HER-2-and therefore, represent a cell culture model for the Luminal A molecular subtype of clinical breast cancer.
Study Rationale II
• Luminal A breast cancer represents an endocrine therapy responsive cancer subtype (1, 2) .
• This subtype of clinical breast cancer responds to conventional systemic therapy comprising of selective estrogen receptor modulators or aromatase inhibitors with or without cytotoxic chemotherapy (3, 4).
• Conventional chemo-endocrine therapy is associated with acquired tumor resistance and long-term systemic toxicity (4).
Study Rationale III
• Nutritional herbs have been widely used in Chinese medicine for a variety of health conditions, including cancer in women (5-8).
• Naturally occurring phytochemicals and herbal products exhibit little systemic toxicity but interact with conventional chemo-endocrine therapy to enhance their efficacy and reduce toxicity (9).
• Epimedium grandiflorum is a nutritional Chinese herb with no documented toxicity, and may therefore be suitable for long-term prevention of breast cancer " "
Experimental Model
• The estrogen dependent ER+ MCF-7 cell line represents a well-established cell culture model for hormone responsive clinical breast cancer (10).
• MCF-7 cells adapted to grow in a chemically defined, serum depleted culture medium retain their responsiveness to 17β-estradiol (E2), and exhibit a positive growth inhibitory response to several mechanistically distinct herbal extracts (11-16).
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Preparation of Non-fractionated Extract from Epimedium grandiflorum (EG)
• Extract # 1: 20 g of EG boiled in 200ml of distilled water to reduce the volume to 100 ml.
• Extract # 2: Residue from extract # 1 boiled in 100 ml of distilled water to reduce the volume to 50 ml.
• Extract # 1 and Extract # 2 combined (Total volume 150 ml) and boiled to reduce the volume to 25 ml.
• The combined extracts centrifuged (5,000 rpm at room temp.) to collect the supernatant (20 ml). This aqueous supernatant served as the stock solution (100%).
• The stock solution diluted with the culture medium to obtain 2%, 1%, 0.5%, 0.05%, 0.02% and 0.01% concentrations of EG.
• The diluted working solutions used to determine the IC50 and maximum cytostatic concentrations of EG on MCF-7 cells.
Mechanistic End point Biomarkers
• Cytostatic growth arrest (number of viable cells)
• Cell cycle progression (G1: S+G2/M ratio)
• Cellular metabolism of 17ß-estradiol (2-OHE1: 16α-OHE1 and E3: 16α-OHE1 ratios) • Anchorage independent growth (number of anchorage independent colonies)
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Figure 1 Dose Response of 17ß-estradiol (E2) on human mammary carcinoma derived MCF-7 Cells
Viable Cell Number (x105) ! 
